PBIO

75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up Scheduled for Early 2023 – Expected to Yield 1^st Half 2023 Revenues Over $1 Million

SOUTH EASTON, MA / ACCESSWIRE / December 13, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics, and food/beverage industries, among others, today confirmed the shipment of the Company’s first ever commercial production lot of a revolutionary nanoemulsion product created and enabled by the Company’s innovative Ultra Shear Technology™ (UST™ or UltraShear™) nanoemulsification platform. The shipped product is a breakthrough CBD oral spray designed by PBI for fast effect and high potency for Safer Medical of Montana (“SMM”), with whom PBI signed a multi-year development and manufacturing agreement (“Agreement”), announced on May 4, 2022. SMM pre-paid the entire $75,000 purchase price of the Phase I production lot.

The Agreement covers three phases of development and commercialization of a custom-formulated oral spray of hemp-derived nanoemulsified CBD designed for extremely rapid absorption and effectiveness, and for efficient high potency delivery of CBD active material in each dose. All ingredients used in the manufacture of this UltraShear prepared nanoemulsion product are sourced from naturally-occurring, plant-based origins. Phases II and III of the PBI-SMM Agreement are focused on scaling up UltraShear nanoemulsion production by a factor of 10x in each stage, with total PBI revenues captured under this Agreement expected to top $1M in Q1/Q2 of 2023.

Captain George Ackerson, the CEO and Founder of Safer Medical of Montana, stated: “I am so excited by our opportunity to partner with Pressure BioSciences in allowing the launch of their first UltraShear-enabled nanoemulsion product to be focused upon creation of our revolutionary “Black Ops Nano CBD” oral spray, which is specifically targeted to serving vast unmet needs within the U.S. veterans community. Their UltraShear technology platform allows an oil-soluble active molecule like CBD to be prepared into a nanoemulsion of vanishingly tiny oil droplets in water that ensures rapid absorption and unparalleled bioavailability of the CBD into the water-based biochemistry of human bodies. Development work to date has demonstrated these capabilities far beyond any CBD products currently on the market – with performance better than we could have dreamed.”

Captain Ackerson continued: “As a Vietnam veteran myself, I wanted to make certain that our CBD product had the best chance of helping the men and women who have served our Country, many of whom still struggle daily with significant health and wellness issues. To ensure optimal effectiveness with fast validation in a positive first use experience, we requested the development of a very high concentration of CBD (40mg per milliliter), which is beyond the concentration capabilities of currently marketed true nano formulations. Each bottle contains 2000mg of CBD. One spray will deliver about 6.5mg of the nanoemulsified CBD, designed for fast absorption through the cheek or under the tongue. Individual users will be able to adjust their dosage easily and rapidly as needed.”

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “This launches a new chapter for Pressure BioSciences, as UltraShear commercialization enters into a phase of scale up and rapid growth. PBI has long established itself as an expert in the development and application of extreme high-pressure technology to enable remarkable and important new scientific and production capabilities, but UltraShear now opens an extraordinarily broad range of important and large new commercial application markets, from pharmaceuticals to nutraceuticals, cosmetics, food and beverages, agrochemicals, and many more.”

Mr. Hollister continued: “Black Ops Nano CBD is the first UltraShear product, but vastly more products, far beyond this initial cannabinoid opportunity, will quickly follow. We have previously announced exciting progress in our cosmeceutical partnership with Dr. Denese SkinScience, and in our formulation developments for astaxanthin (the most potent antioxidant in the market) and other nutraceuticals. Our investors should expect to hear much more about additional UltraShear contracts and products in the days and weeks ahead. The dam is bursting.”

Mr. Richard T. Schumacher, President and CEO of PBI, concluded: We recently announced the first three cosmeceutical products targeted for development and commercialization with Dr. Adrienne Denese through the initial quarters of 2023 PBIO/Dr. Denese FORCE Webinar 101322. Combined with the CBD product formulations already announced with orders from Captain Ackerman and other partners, we expect these UltraShear products to yield at least $4 million of incremental new toll manufacturing revenues for PBI through Q1/Q2 of 2023. We are also close to executing a number of additional UltraShear contracts that we anticipate will drive Q3/Q4 2023 tolling revenues well beyond the expected Q1/Q2 record revenues created by the UltraShear platform. This is a wonderful time to consider becoming or being a stakeholder in Pressure BioSciences.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Chairman (650) 703-8557(T)

SOURCE: Pressure BioSciences Inc.

Phoenix, Arizona–(Newsfile Corp. – December 5, 2022) – The Stock Day Podcast recently welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or “the Company”), a leader in the development and sale of innovative, broadly enabling, high-pressure-based instruments, consumables, and specialty process development and production services for the worldwide life sciences markets and other industries. PBI’s CEO Mr. Richard T. Schumacher, joined Stock Day host Mr. Everett Jolly to explain and highlight important recent developments and progress with its Ultra Shear Technology™ (UST™ or UltraShear™) platform.

Mr. Jolly began by asking about the Company’s decision to make a critical pivot in their business model. “PBIO is a publicly traded company on the OTCQB,” said Mr. Schumacher, “which has established astonishingly broad and strong intellectual property and early commercial penetration, with three different extremely-high-pressure enabling technology platforms. While we were growing the trial and adoption of our game-changing technology platforms across life sciences application areas, it became clear that UltraShear for nanoemulsions was our breakaway opportunity to quickly establish dominant technology differentiation in markets that we believed could be 10-100x larger than our earlier targeted market areas. In the past year, we have pivoted about 90% of our corporate resources onto accelerating the development of the UltraShear technology and penetration of the large and diverse markets that it serves with nanoemulsions of oil-based active molecules in water, including pharmaceuticals, nutraceuticals, cosmeceuticals, food and beverages, agrochemicals, industrial products, and more.”

Mr. Schumacher expanded: “We have established ourselves as the leading innovator in harnessing extreme-pressure processing and transformations of materials routinely and safely. We now have 30 issued patents across our platforms, with seven of them secured around our unique UltraShear platform, which combines ultra-high pressure with very intense liquid shearing forces – to, quite simply, make oil effectively and stably dissolve into water for vastly improved speed and effectiveness in delivery of benefits.”

Mr. Jolly then inquired about the Company’s potential within the vibrantly growing CBD industry. Mr. Schumacher explained: “We are literally now producing our first batch of an oral spray CBD product, with pilot production underway and shipping to follow in the first week or so of December – meeting our announced fourth quarter objective of making and selling our first commercial UltraShear product. The markets that UltraShear addresses span an enormous universe of oil-based active ingredients, including CBD, but also ingredients like vitamins, antioxidants, foods, pharmaceuticals, and more. A significant number of all new pharmaceuticals being developed are oil-based active molecules and getting those critical therapeutic ingredients out of oil and effectively absorbed by our bodies has always been the pivotal challenge,” explained Mr. Schumacher. “With our Ultra Shear Technology, we have upended that paradigm to provide unprecedented speed and completeness of payload delivery.”

Mr. Schumacher continued: “We have signed three contracts for supplying large volumes of bulk nano-CBD to processors to help them scale up production of nanoemulsified CBD in products for consumers. CBD has developed rapid popularity for a diverse portfolio of beneficial effects for consumers, while the companies supplying these products continue to struggle to achieve the benefits of truly consistent and fine nano-droplet emulsions technology. PBI has demonstrated successful and efficiently scalable production of high-quality CBD nanoemulsified products that have also proven to be rock-solid stable as nanoemulsions for over 2.5 years. Following our first commercial batch of CBD production that will be shipped to the distributor in early December, we expect to make a second pilot production batch of a topical CBD product before the end of the year for a second distributor.”

Mr. Jolly then asked how PBI developed its recently announced deal with one of the top skincare companies in the world. Mr. Schumacher replied: “Over many months we have carefully developed and in August finally inked an agreement with Dr. Denese Skin Science, which has sold over half a billion dollars in innovative skincare products on QVC over the past 20 years. Its founder, Dr. Adrienne Denese, is both an MD and a PhD, and is recognized as one of the top skincare scientists in the world. She is intensely focused on product performance and value and understands the critical importance of making ALL of the important oil-soluble therapeutics and nutrients in her skincare products more effectively available through the layers of the skin. Dr. Denese confirmed that using UltraShear nanoemulsions would provide a transformational enhancement to her already market-leading products and has quickly prioritized the development and rollout of three initial products.”

Mr. Jolly asked about the timeline for this rollout. Mr. Schumacher shared: “We anticipate that within the next six months, we expect to have a nanoemulsified oil-soluble vitamin C, for faster and deeper penetration into the skin. We should also have an enhanced retinol product ready for Dr. Denese, which is used in many skincare products. Most exciting of all, our third planned product, targeted for launch by Dr. Denese Skin Science within the next 12 months, is a hair loss supplement expected to provide revolutionary new levels of effectiveness in stopping hair loss and promoting regrowth, all based on our UltraShear technology process.”

Mr. Schumacher closed the interview: “This is the new Pressure BioSciences being revealed. Our original two technology platforms and their 23 patents will continue to support growth in their target markets, but the majority of our efforts will be focused on UltraShear. We already have signed contracts in hand worth an estimated $3-$5 million dollars in incremental revenues for 2023. We expect to announce many more in the coming months, and I strongly encourage our listeners and shareholders to keep up-to-date on our current projects and announcements.”

Mr. Jolley then congratulated Mr. Schumacher on the measurable progress that PBIO has made over the past few months, reminded listeners that Mr. Schumacher had mentioned that additional progress in several areas is expected before the end of 2022, and advised listeners that in his opinion PBIO is a stock they should continue to follow very closely as they may want to consider adding it to their portfolio.

To hear Mr. Richard T. Schumacher’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/8207544-pressure-biosciences-securing-and-fulfilling-ultrashear-nanoemulsions-contracts-discussed-on-st.

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com.

Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Board Chairman (650) 703-8557 (T)
Adrienne Denese, M.D., Ph.D., President of Dr. Denese SkinScience (888) 220-0303 (T)

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146751

SOURCE Stock Day Media

https://api.newsfilecorp.com/newsinfo/146751/130

Ohio State Food Research Leaders Present Critical UST Process Applications, Scalability, and Cleaning

Validation Results for Food Safety, Stability, and Experiential Optimization; System Launching in Q4 2022

SOUTH EASTON, MA / ACCESSWIRE / September 27, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide food and beverage, health and wellness, nutraceuticals, cosmetics, and other industries, today highlighted two significant presentations given at the Conference of Food Engineering 2022 by a distinguished research team at the College of Food, Agricultural, and Environmental Sciences at The Ohio State University and co-authored by members of PBI’s R&D and Engineering teams. These presentations continued to reinforce the dramatic benefits of PBI’s revolutionary Ultra Shear Technology™ (UST™) platform for optimizing food safety, preservation, stability, and consumer sensory experience. More importantly, they validated the uniquely easy scalability of PBI’s UST platform and readiness to engage with commercial introduction challenges at production scales suitable to serve multi-billion-dollar applications and markets.

The Conference of Food Engineering famously provides engineers in the food industry, academia, and government with a widely respected platform for sharing and discussing the latest and most exciting research outcomes and developments affecting the food and beverages industry. Participants include leading researchers from universities across the U.S., as well as from Europe, Asia/Pacific, Africa, and Latin America. Participation and integration of food industry research and commercial leaders is strongly featured and welcomed.

World-renowned food science innovator and OSU Professor V.M. (Bala) Balasubramanian delivered a powerful validation of the end-product benefits of UST in food processing, in a presentation titled “Principles of Ultra Shear Technology and Its Application in Processing Clean Label Beverages”. Dr. Bala and his team presented conclusive data summarizing that:

• PBI’s UST platform delivers significant advantages over high-pressure processing (HPP) (est. market $15.5B) and pasteurization in reducing harmful spoilage and disease-causing bacteria in plant protein beverages.
• UST process powerfully reduced droplet/particle size and beneficially modified other key characteristics (e.g., viscosity). One important outcome was enabling the addition of plant-derived pea protein supplements to dairy products, opening new avenues to hotly demanded, nutritionally-fortified, plant protein products.
• UST process opens and promises new avenues to develop novel functional beverages with greatly improved nutritional, safety, and economic characteristics.

The second presentation, titled “Cleaning and Sanitation Method for Pilot-scale UST Equipment for Liquid Food Processing,” was delivered by OSU Ph.D. candidate Hetian Hu and colleagues. The objective of the study was to develop a “clean-in-place” (CIP) protocol for cleaning and sanitizing pilot-scale to commercial-scale UST equipment and to evaluate the efficacy of the protocol, critical issues needed to ensure commercial success. Hu and team concluded:

• The CIP protocol reduced microbial concentration below detection limits for every test location point.
• The developed CIP protocol effectively sanitized the pilot-scale UST equipment, suitable for rapid readiness turnaround between products.
• Future users of UST equipment can benefit from this study by adapting the developed CIP protocol for use in even larger industrial-scale UST processors expected to be commercially-available in the future.

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “We are preparing to release the first UST processed products for commercial partners in the coming weeks. The validation of these recent studies for the commercial readiness of UST for production scale will now throw open the door to accelerating partnerships in countless applications spanning diverse multi-billion-dollar markets, where effective water-solubility of oil-based active ingredients is critical for optimized bioavailability and absorption – including food and beverages, nutraceuticals, cosmetics, agrochem, and pharmaceuticals.”

Mr. Richard T. Schumacher, President and CEO of PBI summarized: “The results of these studies presented by our colleagues at OSU provides strong and invaluable support to our impending commercial launch activities. They highlight the successful achievement of the two critical objectives that we set for ourselves pre-launch, that: (1) the UST platform can provide an efficient and effective route to the manufacture of clean-label nutritional beverages with functional, economic, and sustainability benefits, and (2) the UST BaroShear equipment can be validated to deliver the critical economic criterion of an effective and economical CIP process that can be performed with minimal effort and in compliance with FDA guidelines for food processing, cleaning, and de-contamination.”

Mr. Schumacher concluded: “I am delighted to say that our plans for commercial launch of the UST platform through our east coast tolling site in Q4 2022 are now at ‘All Systems Go!'”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director Sales and Marketing (805) 908-5719 (T)
Kenneth F. Micciche Director Business Development (508) 230-1828(T)
Jeffrey N. Peterson, Board Chairman (650) 703-8557 (T)

SOURCE: Pressure BioSciences Inc.

Company Shifts Primary Business Focus to Revolutionary UST Platform. Expects to Enter FY 2023 with

Ten or More Tolling Contracts. Believes Each Contract Could Generate $1 Million or More in PBI Revenue.

SOUTH EATON, MA / ACCESSWIRE / September 13, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company’s participation in the September 12-14 H. C. Wainwright Annual Global Investor Conference. This conference will feature a number of exciting, rapidly-growing public and private companies, presenting for 30 minutes each. PBI’s President and CEO, Mr. Richard T. Schumacher, will be speaking on September 13^th at 1:30 pm ET.

Over the past four months, PBI has announced the execution of three agreements covering the production, distribution, commercial roll-out, and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use. Recently, the Company also announced the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with over $500 million in QVC sales.

All four contracts are based on the use of the Company’s patented, Ultra Shear Technology (UST) platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The Company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The Company plans to close on a minimum of six additional contracts over the remaining months of FY 2022.

DATE: Tuesday, September 13, 2022 (1:30 pm ET)

PRESENTATION: Video Webcast – Presentation plus Q&A

REGISTER: Link to PBIO Presentation – HCW Investor Conf.

Highlights of PBI’s Recent Press Releases on the Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Products – with Estimated Annual 2023 Revenue to PBI Expected to Exceed $5,000,000:

• PBI has executed three contracts that call for the Company to manufacture thousands of liters of UST-processed CBD nanoemulsion bulk material during Q4 2022
• CBD bulk nanoemulsion material will be sent to the Company’s contractors who will vial, label, sell, and distribute the material via their e-commerce sites, sub-distributors, and other established sales channels
• These unique products are expected to be long-term stable, effectively water-soluble, highly bioavailable nanoemulsions of CBD for oral and topical use
• Formulation of the initial products has been completed: only plant-based reagents are used in the products
• Safer Medical of Montana (SMM), Canopy CBD Farms (CCF), and North Star Holdings (NSH) will partner with PBI on production, distribution, commercial roll-out, and financial returns – terms of these partnerships are in agreements that were recently executed by the companies and PBI
• These companies have distribution channels and infrastructure for their current health & wellness products
• PBI believes first-year sales (FY 2023) will meet or exceed $5M in revenue for PBI
• PBI believes no other CBD product on the market can compete with the quality of its UST-processed Nano-CBD
• PBI has also announced a partnership with Dr. Denese SkinScience to manufacture new and to enhance existing skincare products sold under the Dr. Denese label. UST-processed products are expected for FY 2023 release.

About H.C. Wainwright

H.C. Wainwright is a fullservice investment bank dedicated to providing corporate finance, strategic advisory, corporate access, and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides equity research and sales & trading services to institutional investors. According to Placement Tracker, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the Internet at www.hcwco.com

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g. oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

SOURCE: Pressure BioSciences Inc.

Canopy CBD Farms, MA-licensed North American Processor/Manufacturer/Distributor of CBD Products Derived from Hemp, Received State Approval Covering PBI’s Manufacture of CBD Nanoemulsions for Sale to MA and Nationwide Formulators and Manufacturers of Hemp-Derived CBD Products

SOUTH EASTON, MA / ACCESSWIRE / August 11, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochemical, and food & beverage industries, today announced approval for its South Easton MA facility to manufacture custom, compliant, hemp-derived CBD nanoemulsions under the processing/manufacturing license of its commercial partner, Canopy CBD Farms, Fitchburg, MA.

Canopy CBD Farms (“CCF”) is a Massachusetts licensed hemp processing and manufacturing company. Foreseeing the future of government regulations, CCF has strategically aligned itself with established FDA registered laboratories and manufacturers to bring the highest of standards and quality of hemp-derived CBD products. Canopy CBD Farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers. CCF’s partnerships will increase wholesale and retail distribution channels, with a ready-to-label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries.

Mr. John Westlake, Founder and President of CCF, commented, “I am delighted to partner with PBI by extending my CBD processing and manufacturing license to PBI’s South Easton location. I firmly believe I can leverage my many years in the cannabis market and hundreds of industry connections to help PBI get quickly and efficiently to market with their unique, highly stable, and water-soluble hemp-derived CBD nanoemulsions, processed using their world-class UST platform.”

Using the Company’s patented Ultra Shear Technology™ (“UST™”) platform, PBI will manufacture and sell – through a tolling processing center located in their South Easton MA facility – a new generation of effectively water-soluble hemp-derived CBD nanoemulsions, in bulk format. Expected to be purchased primarily by formulators and manufacturers, both in MA and throughout the U.S., PBI’s nano-CBD is expected to introduce revolutionary precise and efficient dosing of hemp-derived, nanoemulsified CBD in a wide variety of shelf-stable, clean-label (containing no chemical preservatives) products, encompassing the nutraceuticals, personal care products, cosmetics, and food/beverage markets, to name a few.

Mr. Kenneth F. Micciche, Director of Business Development at PBI, stated: “We are thrilled that our facility has been inspected and approved by the Mass. Dept. of Agricultural Resources (“MDAR”). We can now begin a new phase for our business, to produce and deliver the finest available water-soluble hemp-derived CBD nanoemulsions for use in thousands of products, in MA and throughout the U.S. We believe our nano-CBD will deliver unprecedented up-take, quality, potency, and reliable dosage control and delivery. CCF’s MDAR license – required to process hemp-derived CBD in MA – enables PBI to begin to fulfill the customer demand and signed production contracts that we previously announced, and the many new ones to come, for the highest quality CBD nanoemulsions in a global market estimated to reach $16.6 billion by 2027.”

Mr. Richard T. Schumacher, President and CEO of PBI summarized: “We believe our UST technology platform, coupled with CCF’s license to process/manufacture in MA and John’s impressive experience and remarkable contacts in the cannabis field, will greatly support the launch of our tolling service model, driven by the delivery of high value, UST-processed CBD nanoemulsion products that provide an improved experience derived from enhanced quality and bioavailability.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director Sales and Marketing (805) 908-5719 (T)
Kenneth F. Micciche Director Business Development (508) 230-1828(T)
John Westlake, President & Founder, Canopy CBD Farms, LLC. (978) 471-9981 (T)

SOURCE: Pressure BioSciences Inc.

Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Update/Q&A Session

SOUTH EASTON, MA / ACCESSWIRE / July 6, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company’s participation in the July 6^th Emerging Growth Investor Conference. This real-time, interactive conference will feature a number of exciting, rapidly-growing publicly traded companies, presenting for 30-45 minutes each. PBI’s President and CEO, Mr. Richard T. Schumacher, will be speaking at 10:30 am ET. Mr. Schumacher will briefly expand on the Company’s recent announcement of its contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use.

Last week, PBI announced the execution of an agreement with Safer Medical of Montana (“SMM”) covering the production, distribution, commercial roll-out, and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM’s roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under this agreement, PBI expects to realize more than $1M in revenue from SMM’s $3M sales target. This is the first commercial product produced and marketed that uses the Company’s patented Ultra Shear Technology™ (UST™) platform.

DATE: Wednesday, July 6, 2022 (10:30 am ET)
PRESENTATION: Video Webcast – Presentation plus Q&A
REGISTER: Click here to register for the conference

Highlights of PBI’s Recent Press Release on the Contracted Production Launch of a UST-Processed, Nanoemulsified CBD Spray for Oral Use – with Estimated Annual Revenue to PBI Expected to Exceed $1,000,000:

• PBI will release its first ever UST-processed product to the U.S. market over the next few months
• This unique product is a long-term stable, highly water-soluble CBD aerosol spray for oral use
• Formulation of the product has been completed: only plant-based reagents are used in the product
• Safer Medical of Montana (SMM) will partner with PBI on production, distribution, commercial roll-out, and financial returns – terms of this partnership are in an agreement that was recently executed by the companies
• SMM has existing distribution channels and infrastructure for its current health and wellness products
• SMM estimates that first-year sales will meet or exceed $3M with revenue of over $1M belonging to PBI
• SMM believes no other CBD oral spray available today can compete with the quality and water absorbability of the PBI UST-processed nanoemulsified product

About EmergingGrowth.com & the Emerging Growth Conference

Founded in 2009, EmergingGrowth.com quickly became a leading, independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content in identifying emerging growth companies and markets that can be overlooked by the investment community.

The Emerging Growth Conference has proven to be an effective way for publicly traded companies to present and communicate new products, services, and other major announcements to the investment community in an effective and time efficient manner. The audience includes potentially thousands of individual and institutional investors, as well as investment advisors and analysts.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

CONTACT:

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T)

SOURCE: Pressure BioSciences Inc.